argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 543.48 USD -0.3% Market Closed
Market Cap: 32.5B USD

Relative Value

The Relative Value of one ARGX stock under the Base Case scenario is 716.13 USD. Compared to the current market price of 543.48 USD, argenx SE is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARGX Relative Value
Base Case
716.13 USD
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
15
vs Industry
34
Median 3Y
0
Median 5Y
0
Industry
7.1
Forward
9.2
vs History
11
vs Industry
4
Median 3Y
0
Median 5Y
0
Industry
22.9
Forward
46.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
19.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
22.6
vs History
38
vs Industry
11
Median 3Y
6.9
Median 5Y
5.3
Industry
2.7
vs History
15
vs Industry
30
Median 3Y
0
Median 5Y
0
Industry
7.4
Forward
8.3
vs History
15
vs Industry
29
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
15
vs Industry
0
Median 3Y
0
Median 5Y
0
Industry
4.5
Forward
37.1
vs History
6
vs Industry
Median 3Y
0
Median 5Y
0
Industry
4.5
Forward
39
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
3.7
vs History
20
vs Industry
10
Median 3Y
7.3
Median 5Y
5.1
Industry
4.9

Multiples Across Competitors

ARGX Competitors Multiples
argenx SE Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
argenx SE
NASDAQ:ARGX
28.3B USD 12.8 30.9 127.5 137.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
AU
CSL Ltd
ASX:CSL
116.7B AUD 5 27.9 17.2 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/S Multiple
Revenue Growth P/S to Growth
NL
argenx SE
NASDAQ:ARGX
Average P/S: 3 064 808
12.8
39%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 710 712
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 089.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.4
29%
0.6
P/E Multiple
Earnings Growth PEG
NL
argenx SE
NASDAQ:ARGX
Average P/E: 33.8
30.9
28%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBITDA: 31.7
127.5
727%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBIT: 37.1
137.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A